Live Breaking News & Updates on Immunomodulator Tracir

Stay updated with breaking news from Immunomodulator tracir. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Janux Therapeutics Reports Narrower Q1 Loss, Misses Revenue Estimates

Janux Therapeutics Reports Narrower Q1 Loss, Misses Revenue Estimates
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

David Campbell , Immunomodulator Tracir , Company Overview , Janux Therapeutics Inc , Therapeutics Inc , Tumor Activatedt Cell Engager , Tumor Activated Immunomodulator , Business Highlights , Janux Therapeutics ,

BTIG Research Begins Coverage on Janux Therapeutics (NASDAQ:JANX)

BTIG Research initiated coverage on shares of Janux Therapeutics (NASDAQ:JANX – Free Report) in a research note issued to investors on Thursday morning, Marketbeat.com reports. The firm issued a buy rating and a $62.00 target price on the stock. JANX has been the topic of a number of other research reports. Wedbush reissued an outperform […] ....

United States , Immunomodulator Tracir , William Blair , Nisa Investment Advisors , Btig Research , Tower Research Capital , Janux Therapeutics Inc , Cantor Fitzgerald , China Universal Asset Management Co , Janux Therapeutics Company Profile , Barclays Plc , Citigroup Inc , Janux Therapeutics , Free Report , Therapeutics Trading Down , Investment Advisors , Research Capital , Universal Asset Management , Get Free Report , Tumor Activatedt Cell Engager , Tumor Activated Immunomodulator , Janux Therapeutics Daily ,

Janux Therapeutics (NASDAQ:JANX) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Janux Therapeutics (NASDAQ:JANX) Earns Overweight Rating from Analysts at Cantor Fitzgerald
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United States , Immunomodulator Tracir , William Blair , Cantor Fitzgerald , Janux Therapeutics Inc , Janux Therapeutics Company Profile , Exchange Traded Concepts , Barclays Plc , Unisuper Management Pty Ltd , Janux Therapeutics , Free Report , Capital Partners , Super Management Pty Ltd , Traded Concepts , Get Free Report , Tumor Activatedt Cell Engager , Tumor Activated Immunomodulator , Janux Therapeutics Daily ,

Janux Therapeutics' (JANX) "Outperform" Rating Reiterated at Wedbush

Janux Therapeutics (NASDAQ:JANX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by Wedbush in a research note issued on Monday, RTT News reports. They currently have a $53.00 price target on the stock. Wedbush’s price objective would suggest a potential upside of 32.60% from the stock’s current price. A number of other analysts […] ....

Immunomodulator Tracir , William Blair , Tower Research Capital , Janux Therapeutics Company Profile , Janux Therapeutics Inc , Nisa Investment Advisors , Citigroup Inc , Barclays Plc , China Universal Asset Management Co , Janux Therapeutics , Get Free Report , Investment Advisors , Research Capital , Universal Asset Management , Tumor Activatedt Cell Engager , Tumor Activated Immunomodulator , Janux Therapeutics Daily ,